Oncology Product Guide » Brain Cancer

Aggressive Brain Cancer Driven By Two Collaborating Genes, Study

Jim Marino — Wed, 30 Dec 2009 11:55:37 +0000

Researchers of Herbert Irving Comprehensive Cancer Center and the Columbia Initiative in Systems Biology have discovered two genes that appear to work together as master switches to turn on hundreds of other genes that drive the most aggressive forms of brain cancer: they hope their findings will help develop new approaches to treat these incurable tumors. These are the findings of a study published in the advanced online issue of the journal Nature.

For the full story, Click Here

Study shows Avastin can play critical role in treatment of brain cancer

Jim Marino — Thu, 24 Sep 2009 04:21:37 +0000

Roche Holding AG said cancer drug Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer. An analysis of the phase II BRAIN study of Avastin alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma demonstrated that the six months Avastin-based therapy improved patients’ chances of remaining alive without worsening their disease and had additional positive impact on patients.

ImmunoCellular’s Cancer Vaccine Demonstrates Immune Response Against Brain Cancer

Jim Marino — Fri, 02 Jan 2009 12:04:53 +0000

ImmunoCellular Therapeutics, Ltd. has presented preliminary, promising clinical data from a Phase I trial, evaluating ICT-107, the company’s dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. ICT-107 was well tolerated, and no significant adverse events were reported. The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant type of brain cancer. The trial enrolled 19 patients and was conducted at Cedars-Sinai Medical Center.

New technology crosses blood-brain barrier to traet cancer

Jim Marino — Fri, 24 Oct 2008 06:28:35 +0000

A novel drug delivery system has been developed by scientists from the USA, Canada and France which can cross the blood-brain barrier to reach the cancer cells in the brain and kill them. Currently, the technology is in Phase I of its clinical trial. At present, not even 5 % of drugs can cross this barrier. The non-invasive tool is being developed by Angiochem Inc.